查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1867545

治疗性核子医学产品：全球市场份额和排名、总收入和需求预测（2025-2031年）

Therapeutic Nuclear Medicines - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 144 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024年全球治疗性核子药物市场规模估计为38.54亿美元，预计到2031年将达到74.6亿美元，在2025-2031年预测期内的复合年增长率为10.4%。

本报告对近期关税调整和国际策略反制措施对治疗性核子药物跨境产业布局、资本配置模式、区域经济相互依存关係和供应链重组的影响进行了全面评估。

治疗性核医药物是一类利用放射性同位素将细胞毒性放射线直接输送到病变组织（尤其是肿瘤）的药物。这些药物将放射性同位素与标靶分子（例如胜肽、抗体或小分子配体）结合，以高精度发射α射线、β射线或俄歇电子。这种靶向辐射可诱导细胞死亡，同时最大限度地减少对周围健康组织的损伤。治疗性放射性药物对于无法手术或对传统疗法无反应的癌症（例如前列腺癌和神经内分泌肿瘤）有特别的治疗前景。随着精准医学和分子影像技术的快速发展，该领域正成为个人化癌症治疗的重要前沿，兼具临床疗效和巨大的商业性潜力。

在精准医学进步的推动下，治疗性核子医学作为治疗诊断学的基础正蓬勃发展。大型製药企业与放射性同位素供应商之间的合作正在加速新型放射性配体的研发，而突破性产品的监管核准则拓展了治疗选择，并吸引了投资者的目光。政府支持同位素生产、核子物流和加速核准的政策，进一步释放了该产业的潜力，并加速了研发成果向临床实务的转化。

儘管治疗性放射性药物具有临床应用前景，但仍面临许多行业障碍。放射性同位素的采购受到国家战略管制，供应链也受到严格监管。生产和分销必须严格遵守辐射安全、GMP标准和低温运输物流，这构成了很高的进入门槛。此外，医生和患者的认知度较低，导致引进週期较长，因此，对于新参与企业，教育和商业化工作至关重要。

随着肿瘤学朝着分子分型和个人化治疗的方向发展，人们对疗效高且副作用小的治疗方法的需求日益增长。治疗性核子医学正越来越多地被纳入先进的癌症治疗通讯协定中。放射治疗和诊断在医院平台中的日益整合，推动了医疗机构对相关技术的接受和应用。同时，全球製药巨头正在加速研发用于多种适应症的新一代放射性药物，推动临床应用并拓展应用领域。

本报告旨在按地区/国家、类型和应用对全球治疗性核子药物市场进行全面分析，重点关注总销售量、收入、价格、市场份额和主要企业的排名。

本报告以2024年为基准年，对治疗性核医市场规模、估算和预测进行了阐述，单位为销售量（千台）和收入（百万美元），涵盖2020年至2031年的历史数据和预测数据。定量和定性分析将帮助读者制定治疗性核子医学业务和成长策略，评估市场竞争，分析自身在当前市场中的地位，并做出明智的商业决策。

市场区隔

公司

  • Cardinal Health
  • GE Healthcare
  • Lantheus Medical Imaging
  • Bayer
  • Eli Lilly
  • Bracco Imaging
  • Curium Pharma
  • Jubilant Pharmova
  • Aurobindo Pharma
  • Novartis
  • Siemens
  • NTP Radioisotopes
  • ANSTO
  • Polatom
  • China Isotope & Radiation
  • Dongcheng Pharma
  • Saide Bio

按类型分類的细分市场

  • 镭-223
  • 镏-177
  • 碘-131
  • 其他的

应用领域

  • 甲状腺
  • 骨转移
  • 淋巴瘤
  • 其他的

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Therapeutic Nuclear Medicines was estimated to be worth US$ 3854 million in 2024 and is forecast to a readjusted size of US$ 7460 million by 2031 with a CAGR of 10.4% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Therapeutic Nuclear Medicines cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Therapeutic nuclear medicines are a class of pharmaceuticals that utilize radioactive isotopes to deliver cytotoxic radiation directly to diseased tissues, particularly tumors. These agents combine radioisotopes with targeting molecules-such as peptides, antibodies, or small ligands-to emit alpha, beta, or Auger electrons with high precision. This targeted radiation induces cell death while minimizing damage to surrounding healthy tissues. Therapeutic radiopharmaceuticals are especially promising for cancers that are inoperable or unresponsive to conventional therapies, such as prostate cancer and neuroendocrine tumors. With the rapid advances in precision medicine and molecular imaging, this category is emerging as a pivotal frontier in personalized oncology, offering both clinical efficacy and strong commercial potential.

Driven by the advancement of precision medicine, therapeutic nuclear medicines are gaining momentum as a cornerstone of theranostics. Collaborations between major pharmaceutical companies and radioisotope suppliers are accelerating the development of novel radioligands, while regulatory approvals of breakthrough products are expanding the treatment landscape and attracting investor interest. Government policies supporting isotope production, nuclear logistics, and expedited approvals are further unlocking industry potential and enabling faster translation from R&D to clinical practice.

Despite their clinical promise, therapeutic radiopharmaceuticals face considerable industrial barriers. Radioisotope sourcing is restricted due to national strategic controls, and the supply chain is tightly regulated. Manufacturing and distribution require strict compliance with radiation safety, GMP standards, and cold-chain logistics, resulting in high operational thresholds. Additionally, limited awareness among physicians and patients leads to longer adoption cycles, making education and commercialization efforts critical for new entrants.

As oncology moves toward molecular subtyping and individualized treatment, demand is rising for therapies that offer high efficacy with minimal side effects. Therapeutic nuclear medicines are increasingly incorporated into treatment protocols for advanced-stage cancers. The integration of radiotherapy and diagnostics within hospital platforms is enhancing institutional acceptance and adoption. Meanwhile, global pharmaceutical leaders are accelerating the development of next-generation radiopharmaceuticals across multiple indications, driving broader clinical penetration and application scenarios.

This report aims to provide a comprehensive presentation of the global market for Therapeutic Nuclear Medicines, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Therapeutic Nuclear Medicines by region & country, by Type, and by Application.

The Therapeutic Nuclear Medicines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Therapeutic Nuclear Medicines.

Market Segmentation

By Company

  • Cardinal Health
  • GE Healthcare
  • Lantheus Medical Imaging
  • Bayer
  • Eli Lilly
  • Bracco Imaging
  • Curium Pharma
  • Jubilant Pharmova
  • Aurobindo Pharma
  • Novartis
  • Siemens
  • NTP Radioisotopes
  • ANSTO
  • Polatom
  • China Isotope & Radiation
  • Dongcheng Pharma
  • Saide Bio

Segment by Type

  • Radium-223
  • Lutetium-177
  • Iodine-131
  • Other

Segment by Application

  • Thyroid
  • Bone Metastasis
  • Lymphoma
  • Other

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Therapeutic Nuclear Medicines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Therapeutic Nuclear Medicines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Therapeutic Nuclear Medicines in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Therapeutic Nuclear Medicines Product Introduction
  • 1.2 Global Therapeutic Nuclear Medicines Market Size Forecast
    • 1.2.1 Global Therapeutic Nuclear Medicines Sales Value (2020-2031)
    • 1.2.2 Global Therapeutic Nuclear Medicines Sales Volume (2020-2031)
    • 1.2.3 Global Therapeutic Nuclear Medicines Sales Price (2020-2031)
  • 1.3 Therapeutic Nuclear Medicines Market Trends & Drivers
    • 1.3.1 Therapeutic Nuclear Medicines Industry Trends
    • 1.3.2 Therapeutic Nuclear Medicines Market Drivers & Opportunity
    • 1.3.3 Therapeutic Nuclear Medicines Market Challenges
    • 1.3.4 Therapeutic Nuclear Medicines Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Therapeutic Nuclear Medicines Players Revenue Ranking (2024)
  • 2.2 Global Therapeutic Nuclear Medicines Revenue by Company (2020-2025)
  • 2.3 Global Therapeutic Nuclear Medicines Players Sales Volume Ranking (2024)
  • 2.4 Global Therapeutic Nuclear Medicines Sales Volume by Company Players (2020-2025)
  • 2.5 Global Therapeutic Nuclear Medicines Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Therapeutic Nuclear Medicines Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Therapeutic Nuclear Medicines Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Therapeutic Nuclear Medicines
  • 2.9 Therapeutic Nuclear Medicines Market Competitive Analysis
    • 2.9.1 Therapeutic Nuclear Medicines Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Therapeutic Nuclear Medicines Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Therapeutic Nuclear Medicines as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Radium-223
    • 3.1.2 Lutetium-177
    • 3.1.3 Iodine-131
    • 3.1.4 Other
  • 3.2 Global Therapeutic Nuclear Medicines Sales Value by Type
    • 3.2.1 Global Therapeutic Nuclear Medicines Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Therapeutic Nuclear Medicines Sales Value, by Type (2020-2031)
    • 3.2.3 Global Therapeutic Nuclear Medicines Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Therapeutic Nuclear Medicines Sales Volume by Type
    • 3.3.1 Global Therapeutic Nuclear Medicines Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Therapeutic Nuclear Medicines Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Therapeutic Nuclear Medicines Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Therapeutic Nuclear Medicines Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Thyroid
    • 4.1.2 Bone Metastasis
    • 4.1.3 Lymphoma
    • 4.1.4 Other
  • 4.2 Global Therapeutic Nuclear Medicines Sales Value by Application
    • 4.2.1 Global Therapeutic Nuclear Medicines Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Therapeutic Nuclear Medicines Sales Value, by Application (2020-2031)
    • 4.2.3 Global Therapeutic Nuclear Medicines Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Therapeutic Nuclear Medicines Sales Volume by Application
    • 4.3.1 Global Therapeutic Nuclear Medicines Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Therapeutic Nuclear Medicines Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Therapeutic Nuclear Medicines Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Therapeutic Nuclear Medicines Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Therapeutic Nuclear Medicines Sales Value by Region
    • 5.1.1 Global Therapeutic Nuclear Medicines Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Therapeutic Nuclear Medicines Sales Value by Region (2020-2025)
    • 5.1.3 Global Therapeutic Nuclear Medicines Sales Value by Region (2026-2031)
    • 5.1.4 Global Therapeutic Nuclear Medicines Sales Value by Region (%), (2020-2031)
  • 5.2 Global Therapeutic Nuclear Medicines Sales Volume by Region
    • 5.2.1 Global Therapeutic Nuclear Medicines Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Therapeutic Nuclear Medicines Sales Volume by Region (2020-2025)
    • 5.2.3 Global Therapeutic Nuclear Medicines Sales Volume by Region (2026-2031)
    • 5.2.4 Global Therapeutic Nuclear Medicines Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Therapeutic Nuclear Medicines Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Therapeutic Nuclear Medicines Sales Value, 2020-2031
    • 5.4.2 North America Therapeutic Nuclear Medicines Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Therapeutic Nuclear Medicines Sales Value, 2020-2031
    • 5.5.2 Europe Therapeutic Nuclear Medicines Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Therapeutic Nuclear Medicines Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Therapeutic Nuclear Medicines Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Therapeutic Nuclear Medicines Sales Value, 2020-2031
    • 5.7.2 South America Therapeutic Nuclear Medicines Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Therapeutic Nuclear Medicines Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Therapeutic Nuclear Medicines Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Therapeutic Nuclear Medicines Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Therapeutic Nuclear Medicines Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Therapeutic Nuclear Medicines Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Therapeutic Nuclear Medicines Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Therapeutic Nuclear Medicines Sales Value, 2020-2031
    • 6.3.2 United States Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Therapeutic Nuclear Medicines Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Therapeutic Nuclear Medicines Sales Value, 2020-2031
    • 6.4.2 Europe Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Therapeutic Nuclear Medicines Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Therapeutic Nuclear Medicines Sales Value, 2020-2031
    • 6.5.2 China Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Therapeutic Nuclear Medicines Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Therapeutic Nuclear Medicines Sales Value, 2020-2031
    • 6.6.2 Japan Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Therapeutic Nuclear Medicines Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Therapeutic Nuclear Medicines Sales Value, 2020-2031
    • 6.7.2 South Korea Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Therapeutic Nuclear Medicines Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Therapeutic Nuclear Medicines Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Therapeutic Nuclear Medicines Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Therapeutic Nuclear Medicines Sales Value, 2020-2031
    • 6.9.2 India Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Therapeutic Nuclear Medicines Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Cardinal Health
    • 7.1.1 Cardinal Health Company Information
    • 7.1.2 Cardinal Health Introduction and Business Overview
    • 7.1.3 Cardinal Health Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Cardinal Health Therapeutic Nuclear Medicines Product Offerings
    • 7.1.5 Cardinal Health Recent Development
  • 7.2 GE Healthcare
    • 7.2.1 GE Healthcare Company Information
    • 7.2.2 GE Healthcare Introduction and Business Overview
    • 7.2.3 GE Healthcare Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 GE Healthcare Therapeutic Nuclear Medicines Product Offerings
    • 7.2.5 GE Healthcare Recent Development
  • 7.3 Lantheus Medical Imaging
    • 7.3.1 Lantheus Medical Imaging Company Information
    • 7.3.2 Lantheus Medical Imaging Introduction and Business Overview
    • 7.3.3 Lantheus Medical Imaging Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Lantheus Medical Imaging Therapeutic Nuclear Medicines Product Offerings
    • 7.3.5 Lantheus Medical Imaging Recent Development
  • 7.4 Bayer
    • 7.4.1 Bayer Company Information
    • 7.4.2 Bayer Introduction and Business Overview
    • 7.4.3 Bayer Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 Bayer Therapeutic Nuclear Medicines Product Offerings
    • 7.4.5 Bayer Recent Development
  • 7.5 Eli Lilly
    • 7.5.1 Eli Lilly Company Information
    • 7.5.2 Eli Lilly Introduction and Business Overview
    • 7.5.3 Eli Lilly Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 Eli Lilly Therapeutic Nuclear Medicines Product Offerings
    • 7.5.5 Eli Lilly Recent Development
  • 7.6 Bracco Imaging
    • 7.6.1 Bracco Imaging Company Information
    • 7.6.2 Bracco Imaging Introduction and Business Overview
    • 7.6.3 Bracco Imaging Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 Bracco Imaging Therapeutic Nuclear Medicines Product Offerings
    • 7.6.5 Bracco Imaging Recent Development
  • 7.7 Curium Pharma
    • 7.7.1 Curium Pharma Company Information
    • 7.7.2 Curium Pharma Introduction and Business Overview
    • 7.7.3 Curium Pharma Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Curium Pharma Therapeutic Nuclear Medicines Product Offerings
    • 7.7.5 Curium Pharma Recent Development
  • 7.8 Jubilant Pharmova
    • 7.8.1 Jubilant Pharmova Company Information
    • 7.8.2 Jubilant Pharmova Introduction and Business Overview
    • 7.8.3 Jubilant Pharmova Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 Jubilant Pharmova Therapeutic Nuclear Medicines Product Offerings
    • 7.8.5 Jubilant Pharmova Recent Development
  • 7.9 Aurobindo Pharma
    • 7.9.1 Aurobindo Pharma Company Information
    • 7.9.2 Aurobindo Pharma Introduction and Business Overview
    • 7.9.3 Aurobindo Pharma Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.9.4 Aurobindo Pharma Therapeutic Nuclear Medicines Product Offerings
    • 7.9.5 Aurobindo Pharma Recent Development
  • 7.10 Novartis
    • 7.10.1 Novartis Company Information
    • 7.10.2 Novartis Introduction and Business Overview
    • 7.10.3 Novartis Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.10.4 Novartis Therapeutic Nuclear Medicines Product Offerings
    • 7.10.5 Novartis Recent Development
  • 7.11 Siemens
    • 7.11.1 Siemens Company Information
    • 7.11.2 Siemens Introduction and Business Overview
    • 7.11.3 Siemens Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.11.4 Siemens Therapeutic Nuclear Medicines Product Offerings
    • 7.11.5 Siemens Recent Development
  • 7.12 NTP Radioisotopes
    • 7.12.1 NTP Radioisotopes Company Information
    • 7.12.2 NTP Radioisotopes Introduction and Business Overview
    • 7.12.3 NTP Radioisotopes Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.12.4 NTP Radioisotopes Therapeutic Nuclear Medicines Product Offerings
    • 7.12.5 NTP Radioisotopes Recent Development
  • 7.13 ANSTO
    • 7.13.1 ANSTO Company Information
    • 7.13.2 ANSTO Introduction and Business Overview
    • 7.13.3 ANSTO Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.13.4 ANSTO Therapeutic Nuclear Medicines Product Offerings
    • 7.13.5 ANSTO Recent Development
  • 7.14 Polatom
    • 7.14.1 Polatom Company Information
    • 7.14.2 Polatom Introduction and Business Overview
    • 7.14.3 Polatom Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.14.4 Polatom Therapeutic Nuclear Medicines Product Offerings
    • 7.14.5 Polatom Recent Development
  • 7.15 China Isotope & Radiation
    • 7.15.1 China Isotope & Radiation Company Information
    • 7.15.2 China Isotope & Radiation Introduction and Business Overview
    • 7.15.3 China Isotope & Radiation Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.15.4 China Isotope & Radiation Therapeutic Nuclear Medicines Product Offerings
    • 7.15.5 China Isotope & Radiation Recent Development
  • 7.16 Dongcheng Pharma
    • 7.16.1 Dongcheng Pharma Company Information
    • 7.16.2 Dongcheng Pharma Introduction and Business Overview
    • 7.16.3 Dongcheng Pharma Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.16.4 Dongcheng Pharma Therapeutic Nuclear Medicines Product Offerings
    • 7.16.5 Dongcheng Pharma Recent Development
  • 7.17 Saide Bio
    • 7.17.1 Saide Bio Company Information
    • 7.17.2 Saide Bio Introduction and Business Overview
    • 7.17.3 Saide Bio Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.17.4 Saide Bio Therapeutic Nuclear Medicines Product Offerings
    • 7.17.5 Saide Bio Recent Development

8 Industry Chain Analysis

  • 8.1 Therapeutic Nuclear Medicines Industrial Chain
  • 8.2 Therapeutic Nuclear Medicines Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Therapeutic Nuclear Medicines Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Therapeutic Nuclear Medicines Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Therapeutic Nuclear Medicines Market Trends
  • Table 2. Therapeutic Nuclear Medicines Market Drivers & Opportunity
  • Table 3. Therapeutic Nuclear Medicines Market Challenges
  • Table 4. Therapeutic Nuclear Medicines Market Restraints
  • Table 5. Global Therapeutic Nuclear Medicines Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Therapeutic Nuclear Medicines Revenue Market Share by Company (2020-2025)
  • Table 7. Global Therapeutic Nuclear Medicines Sales Volume by Company (2020-2025) & (K Units)
  • Table 8. Global Therapeutic Nuclear Medicines Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Therapeutic Nuclear Medicines Price by Company (2020-2025) & (USD/Unit)
  • Table 10. Key Manufacturers Therapeutic Nuclear Medicines Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Therapeutic Nuclear Medicines Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Therapeutic Nuclear Medicines
  • Table 13. Global Therapeutic Nuclear Medicines Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Therapeutic Nuclear Medicines as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Therapeutic Nuclear Medicines Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Therapeutic Nuclear Medicines Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Therapeutic Nuclear Medicines Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Therapeutic Nuclear Medicines Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Therapeutic Nuclear Medicines Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Therapeutic Nuclear Medicines Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)
  • Table 22. Global Therapeutic Nuclear Medicines Sales Volume by Type (2020-2025) & (K Units)
  • Table 23. Global Therapeutic Nuclear Medicines Sales Volume by Type (2026-2031) & (K Units)
  • Table 24. Global Therapeutic Nuclear Medicines Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Therapeutic Nuclear Medicines Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Therapeutic Nuclear Medicines Price by Type (2020-2025) & (USD/Unit)
  • Table 27. Global Therapeutic Nuclear Medicines Price by Type (2026-2031) & (USD/Unit)
  • Table 28. Global Therapeutic Nuclear Medicines Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Therapeutic Nuclear Medicines Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Therapeutic Nuclear Medicines Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Therapeutic Nuclear Medicines Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Therapeutic Nuclear Medicines Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Therapeutic Nuclear Medicines Sales Volume by Application: 2020 VS 2024 VS 2031 (K Units)
  • Table 34. Global Therapeutic Nuclear Medicines Sales Volume by Application (2020-2025) & (K Units)
  • Table 35. Global Therapeutic Nuclear Medicines Sales Volume by Application (2026-2031) & (K Units)
  • Table 36. Global Therapeutic Nuclear Medicines Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Therapeutic Nuclear Medicines Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Therapeutic Nuclear Medicines Price by Application (2020-2025) & (USD/Unit)
  • Table 39. Global Therapeutic Nuclear Medicines Price by Application (2026-2031) & (USD/Unit)
  • Table 40. Global Therapeutic Nuclear Medicines Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Therapeutic Nuclear Medicines Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Therapeutic Nuclear Medicines Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Therapeutic Nuclear Medicines Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Therapeutic Nuclear Medicines Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Therapeutic Nuclear Medicines Sales Volume by Region (K Units): 2020 VS 2024 VS 2031
  • Table 46. Global Therapeutic Nuclear Medicines Sales Volume by Region (2020-2025) & (K Units)
  • Table 47. Global Therapeutic Nuclear Medicines Sales Volume by Region (2026-2031) & (K Units)
  • Table 48. Global Therapeutic Nuclear Medicines Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Therapeutic Nuclear Medicines Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Therapeutic Nuclear Medicines Average Price by Region (2020-2025) & (USD/Unit)
  • Table 51. Global Therapeutic Nuclear Medicines Average Price by Region (2026-2031) & (USD/Unit)
  • Table 52. Key Countries/Regions Therapeutic Nuclear Medicines Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Therapeutic Nuclear Medicines Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Therapeutic Nuclear Medicines Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Therapeutic Nuclear Medicines Sales Volume, (2020-2025) & (K Units)
  • Table 56. Key Countries/Regions Therapeutic Nuclear Medicines Sales Volume, (2026-2031) & (K Units)
  • Table 57. Cardinal Health Company Information
  • Table 58. Cardinal Health Introduction and Business Overview
  • Table 59. Cardinal Health Therapeutic Nuclear Medicines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 60. Cardinal Health Therapeutic Nuclear Medicines Product Offerings
  • Table 61. Cardinal Health Recent Development
  • Table 62. GE Healthcare Company Information
  • Table 63. GE Healthcare Introduction and Business Overview
  • Table 64. GE Healthcare Therapeutic Nuclear Medicines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 65. GE Healthcare Therapeutic Nuclear Medicines Product Offerings
  • Table 66. GE Healthcare Recent Development
  • Table 67. Lantheus Medical Imaging Company Information
  • Table 68. Lantheus Medical Imaging Introduction and Business Overview
  • Table 69. Lantheus Medical Imaging Therapeutic Nuclear Medicines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 70. Lantheus Medical Imaging Therapeutic Nuclear Medicines Product Offerings
  • Table 71. Lantheus Medical Imaging Recent Development
  • Table 72. Bayer Company Information
  • Table 73. Bayer Introduction and Business Overview
  • Table 74. Bayer Therapeutic Nuclear Medicines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 75. Bayer Therapeutic Nuclear Medicines Product Offerings
  • Table 76. Bayer Recent Development
  • Table 77. Eli Lilly Company Information
  • Table 78. Eli Lilly Introduction and Business Overview
  • Table 79. Eli Lilly Therapeutic Nuclear Medicines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 80. Eli Lilly Therapeutic Nuclear Medicines Product Offerings
  • Table 81. Eli Lilly Recent Development
  • Table 82. Bracco Imaging Company Information
  • Table 83. Bracco Imaging Introduction and Business Overview
  • Table 84. Bracco Imaging Therapeutic Nuclear Medicines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 85. Bracco Imaging Therapeutic Nuclear Medicines Product Offerings
  • Table 86. Bracco Imaging Recent Development
  • Table 87. Curium Pharma Company Information
  • Table 88. Curium Pharma Introduction and Business Overview
  • Table 89. Curium Pharma Therapeutic Nuclear Medicines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 90. Curium Pharma Therapeutic Nuclear Medicines Product Offerings
  • Table 91. Curium Pharma Recent Development
  • Table 92. Jubilant Pharmova Company Information
  • Table 93. Jubilant Pharmova Introduction and Business Overview
  • Table 94. Jubilant Pharmova Therapeutic Nuclear Medicines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 95. Jubilant Pharmova Therapeutic Nuclear Medicines Product Offerings
  • Table 96. Jubilant Pharmova Recent Development
  • Table 97. Aurobindo Pharma Company Information
  • Table 98. Aurobindo Pharma Introduction and Business Overview
  • Table 99. Aurobindo Pharma Therapeutic Nuclear Medicines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 100. Aurobindo Pharma Therapeutic Nuclear Medicines Product Offerings
  • Table 101. Aurobindo Pharma Recent Development
  • Table 102. Novartis Company Information
  • Table 103. Novartis Introduction and Business Overview
  • Table 104. Novartis Therapeutic Nuclear Medicines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 105. Novartis Therapeutic Nuclear Medicines Product Offerings
  • Table 106. Novartis Recent Development
  • Table 107. Siemens Company Information
  • Table 108. Siemens Introduction and Business Overview
  • Table 109. Siemens Therapeutic Nuclear Medicines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 110. Siemens Therapeutic Nuclear Medicines Product Offerings
  • Table 111. Siemens Recent Development
  • Table 112. NTP Radioisotopes Company Information
  • Table 113. NTP Radioisotopes Introduction and Business Overview
  • Table 114. NTP Radioisotopes Therapeutic Nuclear Medicines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 115. NTP Radioisotopes Therapeutic Nuclear Medicines Product Offerings
  • Table 116. NTP Radioisotopes Recent Development
  • Table 117. ANSTO Company Information
  • Table 118. ANSTO Introduction and Business Overview
  • Table 119. ANSTO Therapeutic Nuclear Medicines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 120. ANSTO Therapeutic Nuclear Medicines Product Offerings
  • Table 121. ANSTO Recent Development
  • Table 122. Polatom Company Information
  • Table 123. Polatom Introduction and Business Overview
  • Table 124. Polatom Therapeutic Nuclear Medicines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 125. Polatom Therapeutic Nuclear Medicines Product Offerings
  • Table 126. Polatom Recent Development
  • Table 127. China Isotope & Radiation Company Information
  • Table 128. China Isotope & Radiation Introduction and Business Overview
  • Table 129. China Isotope & Radiation Therapeutic Nuclear Medicines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 130. China Isotope & Radiation Therapeutic Nuclear Medicines Product Offerings
  • Table 131. China Isotope & Radiation Recent Development
  • Table 132. Dongcheng Pharma Company Information
  • Table 133. Dongcheng Pharma Introduction and Business Overview
  • Table 134. Dongcheng Pharma Therapeutic Nuclear Medicines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 135. Dongcheng Pharma Therapeutic Nuclear Medicines Product Offerings
  • Table 136. Dongcheng Pharma Recent Development
  • Table 137. Saide Bio Company Information
  • Table 138. Saide Bio Introduction and Business Overview
  • Table 139. Saide Bio Therapeutic Nuclear Medicines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 140. Saide Bio Therapeutic Nuclear Medicines Product Offerings
  • Table 141. Saide Bio Recent Development
  • Table 142. Key Raw Materials Lists
  • Table 143. Raw Materials Key Suppliers Lists
  • Table 144. Therapeutic Nuclear Medicines Downstream Customers
  • Table 145. Therapeutic Nuclear Medicines Distributors List
  • Table 146. Research Programs/Design for This Report
  • Table 147. Key Data Information from Secondary Sources
  • Table 148. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Therapeutic Nuclear Medicines Product Picture
  • Figure 2. Global Therapeutic Nuclear Medicines Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Therapeutic Nuclear Medicines Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Therapeutic Nuclear Medicines Sales Volume (2020-2031) & (K Units)
  • Figure 5. Global Therapeutic Nuclear Medicines Sales Price (2020-2031) & (USD/Unit)
  • Figure 6. Therapeutic Nuclear Medicines Report Years Considered
  • Figure 7. Global Therapeutic Nuclear Medicines Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Therapeutic Nuclear Medicines Players Sales Volume Ranking (2024) & (K Units)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Therapeutic Nuclear Medicines Revenue in 2024
  • Figure 10. Therapeutic Nuclear Medicines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. Radium-223 Picture
  • Figure 12. Lutetium-177 Picture
  • Figure 13. Iodine-131 Picture
  • Figure 14. Other Picture
  • Figure 15. Global Therapeutic Nuclear Medicines Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 16. Global Therapeutic Nuclear Medicines Sales Value Market Share by Type, 2024 & 2031
  • Figure 17. Global Therapeutic Nuclear Medicines Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)
  • Figure 18. Global Therapeutic Nuclear Medicines Sales Volume Market Share by Type, 2024 & 2031
  • Figure 19. Global Therapeutic Nuclear Medicines Price by Type (2020-2031) & (USD/Unit)
  • Figure 20. Product Picture of Thyroid
  • Figure 21. Product Picture of Bone Metastasis
  • Figure 22. Product Picture of Lymphoma
  • Figure 23. Product Picture of Other
  • Figure 24. Global Therapeutic Nuclear Medicines Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 25. Global Therapeutic Nuclear Medicines Sales Value Market Share by Application, 2024 & 2031
  • Figure 26. Global Therapeutic Nuclear Medicines Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)
  • Figure 27. Global Therapeutic Nuclear Medicines Sales Volume Market Share by Application, 2024 & 2031
  • Figure 28. Global Therapeutic Nuclear Medicines Price by Application (2020-2031) & (USD/Unit)
  • Figure 29. North America Therapeutic Nuclear Medicines Sales Value (2020-2031) & (US$ Million)
  • Figure 30. North America Therapeutic Nuclear Medicines Sales Value by Country (%), 2024 VS 2031
  • Figure 31. Europe Therapeutic Nuclear Medicines Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. Europe Therapeutic Nuclear Medicines Sales Value by Country (%), 2024 VS 2031
  • Figure 33. Asia Pacific Therapeutic Nuclear Medicines Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. Asia Pacific Therapeutic Nuclear Medicines Sales Value by Region (%), 2024 VS 2031
  • Figure 35. South America Therapeutic Nuclear Medicines Sales Value, (2020-2031) & (US$ Million)
  • Figure 36. South America Therapeutic Nuclear Medicines Sales Value by Country (%), 2024 VS 2031
  • Figure 37. Middle East & Africa Therapeutic Nuclear Medicines Sales Value, (2020-2031) & (US$ Million)
  • Figure 38. Middle East & Africa Therapeutic Nuclear Medicines Sales Value by Country (%), 2024 VS 2031
  • Figure 39. Key Countries/Regions Therapeutic Nuclear Medicines Sales Value (%), (2020-2031)
  • Figure 40. Key Countries/Regions Therapeutic Nuclear Medicines Sales Volume (%), (2020-2031)
  • Figure 41. United States Therapeutic Nuclear Medicines Sales Value, (2020-2031) & (US$ Million)
  • Figure 42. United States Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
  • Figure 43. United States Therapeutic Nuclear Medicines Sales Value by Application (%), 2024 VS 2031
  • Figure 44. Europe Therapeutic Nuclear Medicines Sales Value, (2020-2031) & (US$ Million)
  • Figure 45. Europe Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
  • Figure 46. Europe Therapeutic Nuclear Medicines Sales Value by Application (%), 2024 VS 2031
  • Figure 47. China Therapeutic Nuclear Medicines Sales Value, (2020-2031) & (US$ Million)
  • Figure 48. China Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
  • Figure 49. China Therapeutic Nuclear Medicines Sales Value by Application (%), 2024 VS 2031
  • Figure 50. Japan Therapeutic Nuclear Medicines Sales Value, (2020-2031) & (US$ Million)
  • Figure 51. Japan Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
  • Figure 52. Japan Therapeutic Nuclear Medicines Sales Value by Application (%), 2024 VS 2031
  • Figure 53. South Korea Therapeutic Nuclear Medicines Sales Value, (2020-2031) & (US$ Million)
  • Figure 54. South Korea Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
  • Figure 55. South Korea Therapeutic Nuclear Medicines Sales Value by Application (%), 2024 VS 2031
  • Figure 56. Southeast Asia Therapeutic Nuclear Medicines Sales Value, (2020-2031) & (US$ Million)
  • Figure 57. Southeast Asia Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
  • Figure 58. Southeast Asia Therapeutic Nuclear Medicines Sales Value by Application (%), 2024 VS 2031
  • Figure 59. India Therapeutic Nuclear Medicines Sales Value, (2020-2031) & (US$ Million)
  • Figure 60. India Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
  • Figure 61. India Therapeutic Nuclear Medicines Sales Value by Application (%), 2024 VS 2031
  • Figure 62. Therapeutic Nuclear Medicines Industrial Chain
  • Figure 63. Therapeutic Nuclear Medicines Manufacturing Cost Structure
  • Figure 64. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 65. Bottom-up and Top-down Approaches for This Report
  • Figure 66. Data Triangulation
  • Figure 67. Key Executives Interviewed